167 related articles for article (PubMed ID: 9466584)
41. Evaluation of new monoclonal anti-MyoD1 and anti-myogenin antibodies for the diagnosis of rhabdomyosarcoma.
Cui S; Hano H; Harada T; Takai S; Masui F; Ushigome S
Pathol Int; 1999 Jan; 49(1):62-8. PubMed ID: 10227726
[TBL] [Abstract][Full Text] [Related]
42. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis.
Petak I; Douglas L; Tillman DM; Vernes R; Houghton JA
Clin Cancer Res; 2000 Oct; 6(10):4119-27. PubMed ID: 11051265
[TBL] [Abstract][Full Text] [Related]
43. Folylpoly-gamma-glutamate synthetase gene mRNA splice variants and protein expression in primary human leukemia cells, cell lines, and normal human tissues.
Leclerc GJ; Barredo JC
Clin Cancer Res; 2001 Apr; 7(4):942-51. PubMed ID: 11309345
[TBL] [Abstract][Full Text] [Related]
44. Detection and clinical significance of disseminated tumour cells at diagnosis in bone marrow of children with localised rhabdomyosarcoma.
McDowell HP; Donfrancesco A; Milano GM; Clerico A; Mannarino O; Altavista P; Boldrini R; Cozza R; Inserra A; Dominici C
Eur J Cancer; 2005 Oct; 41(15):2288-96. PubMed ID: 16169716
[TBL] [Abstract][Full Text] [Related]
45. Identification of various exon combinations of the ews/fli1 translocation: an optimized RT-PCR method for paraffin embedded tissue -- a report by the CWS-study group.
Stegmaier S; Leuschner I; Aakcha-Rudel E; Münch P; Kazanowska B; Bekassy A; Treuner J; Koscielniak E
Klin Padiatr; 2004; 216(6):315-22. PubMed ID: 15565546
[TBL] [Abstract][Full Text] [Related]
46. Detection of occult tumor cells in peripheral blood from patients with small cell lung cancer by reverse transcriptase-polymerase chain reaction.
Bessho A; Tabata M; Kiura K; Takata I; Nagata T; Fujimoto N; Kunisada K; Ueoka H; Harada M
Anticancer Res; 2000; 20(2B):1149-54. PubMed ID: 10810412
[TBL] [Abstract][Full Text] [Related]
47. Variation in cadherins and catenins expression is linked to both proliferation and transformation of Rhabdomyosarcoma.
Charrasse S; Comunale F; Gilbert E; Delattre O; Gauthier-Rouvière C
Oncogene; 2004 Mar; 23(13):2420-30. PubMed ID: 14691446
[TBL] [Abstract][Full Text] [Related]
48. Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.
Schaefer KL; Brachwitz K; Wai DH; Braun Y; Diallo R; Korsching E; Eisenacher M; Voss R; Van Valen F; Baer C; Selle B; Spahn L; Liao SK; Lee KA; Hogendoorn PC; Reifenberger G; Gabbert HE; Poremba C
Cancer Res; 2004 May; 64(10):3395-405. PubMed ID: 15150091
[TBL] [Abstract][Full Text] [Related]
49. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
[TBL] [Abstract][Full Text] [Related]
50. Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assay.
Gallego S; Llort A; Roma J; Sabado C; Gros L; de Toledo JS
J Cancer Res Clin Oncol; 2006 Jun; 132(6):356-62. PubMed ID: 16435141
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathologic features of 300 rhabdomyosarcomas with emphasis upon differential expression of skeletal muscle specific markers in the various subtypes: A single institutional experience.
Rekhi B; Gupta C; Chinnaswamy G; Qureshi S; Vora T; Khanna N; Laskar S
Ann Diagn Pathol; 2018 Oct; 36():50-60. PubMed ID: 30098515
[TBL] [Abstract][Full Text] [Related]
52. The expanding morphological and genetic spectrum of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non-mutated cases.
Tsai JW; ChangChien YC; Lee JC; Kao YC; Li WS; Liang CW; Liao IC; Chang YM; Wang JC; Tsao CF; Yu SC; Huang HY
Histopathology; 2019 May; 74(6):933-943. PubMed ID: 30604891
[TBL] [Abstract][Full Text] [Related]
53. Optimization of rhabdomyosarcoma disseminated disease assessment by flow cytometry.
Almazán-Moga A; Roma J; Molist C; Vidal I; Jubierre L; Soriano A; Segura MF; Llort A; Sánchez de Toledo J; Gallego S
Cytometry A; 2014 Dec; 85(12):1020-9. PubMed ID: 25155056
[TBL] [Abstract][Full Text] [Related]
54. Methylation alterations of the MyoD1 upstream region are predictive of subclassification of human rhabdomyosarcomas.
Chen B; Dias P; Jenkins JJ; Savell VH; Parham DM
Am J Pathol; 1998 Apr; 152(4):1071-9. PubMed ID: 9546368
[TBL] [Abstract][Full Text] [Related]
55. Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.
Ting MA; Reuther J; Chandramohan R; Voicu H; Gandhi I; Liu M; Cortes-Santiago N; Foster JH; Hicks J; Nuchtern J; Scollon S; Plon SE; Chintagumpala M; Rainusso N; Roy A; Parsons DW
J Pathol; 2021 Sep; 255(1):52-61. PubMed ID: 34086347
[TBL] [Abstract][Full Text] [Related]
56. Caveolin-3 is a sensitive and specific marker for rhabdomyosarcoma.
Fine SW; Lisanti MP; Argani P; Li M
Appl Immunohistochem Mol Morphol; 2005 Sep; 13(3):231-6. PubMed ID: 16082247
[TBL] [Abstract][Full Text] [Related]
57. Differential expression of myogenic regulatory genes, MyoD1 and myogenin, in human rhabdomyosarcoma sublines.
Hosoi H; Sugimoto T; Hayashi Y; Inaba T; Horii Y; Morioka H; Fushiki S; Hamazaki M; Sawada T
Int J Cancer; 1992 Apr; 50(6):977-83. PubMed ID: 1313401
[TBL] [Abstract][Full Text] [Related]
58. TBX2 blocks myogenesis and promotes proliferation in rhabdomyosarcoma cells.
Zhu B; Zhang M; Byrum SD; Tackett AJ; Davie JK
Int J Cancer; 2014 Aug; 135(4):785-97. PubMed ID: 24470334
[TBL] [Abstract][Full Text] [Related]
59. SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated state.
Hsu JY; Danis EP; Nance S; O'Brien JH; Gustafson AL; Wessells VM; Goodspeed AE; Talbot JC; Amacher SL; Jedlicka P; Black JC; Costello JC; Durbin AD; Artinger KB; Ford HL
Cell Rep; 2022 Feb; 38(5):110323. PubMed ID: 35108532
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of New Monoclonal Anti-MyoD1 (MX049) for the Diagnosis of Rhabdomyosarcoma: Comparison with 5.8A, EP212, Anti-Desmin, Anti-Myogenin, and Fluorescence
He Y; Chen X; Yu X
Ann Clin Lab Sci; 2020 May; 50(3):412-416. PubMed ID: 32581037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
